BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao J, Lei J, Yu J, Zhang C, Song X, Zhang N, Wang Y, Zhang S. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. Invest New Drugs 2020;38:500-6. [PMID: 31650447 DOI: 10.1007/s10637-019-00866-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng S, Shen T, Liu Q, Liu T, Tuerxun A, Zhang Q, Yang L, Han X, Lu X. CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway. J Cell Physiol 2021;236:5373-86. [PMID: 33368292 DOI: 10.1002/jcp.30236] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Jiang D, Xu Y, Chen Y, Jiang J, Wang M, Yang M, Chen Z, Yang L. Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review. Front Pharmacol 2020;11:1027. [PMID: 32765260 DOI: 10.3389/fphar.2020.01027] [Reference Citation Analysis]
3 Peng C, Cohen DJ. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opin Pharmacother 2021;22:93-107. [PMID: 33034212 DOI: 10.1080/14656566.2020.1813278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Su R, Zhu J, Wu S, Luo H, He Y. Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients. Technol Cancer Res Treat 2022;21:15330338211072974. [PMID: 35072577 DOI: 10.1177/15330338211072974] [Reference Citation Analysis]
5 Zhao J, He M, Li J, Li D, Zhao Y, Li X, Zhang X, Chen X, Liu Y, Zhao L. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 34524004 DOI: 10.1089/cbr.2021.0086] [Reference Citation Analysis]
6 Chi D, Chen B, Guo S, Bai K, Ma H, Hu Y, Li Q, Zhu Y. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. Aging (Albany NY) 2021;13:8408-20. [PMID: 33713398 DOI: 10.18632/aging.202652] [Reference Citation Analysis]
7 Cai J, Zhou S, Luo Y, Liu A. Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. Medicine (Baltimore) 2021;100:e28126. [PMID: 34941058 DOI: 10.1097/MD.0000000000028126] [Reference Citation Analysis]